Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation (NASDAQ: RGEN) announced today that it has received approval from the Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy (SMA). SMA is an inherited neurodegenerative disease in which a defect in the SMN1 ("survival motor neuron") gene results in low levels of the protein SMN and leads to progressive damage to motor neurons, loss of muscle function and, in many patients, early death. This is a double-blind study to evaluate the pharmacokinetic and safety profile of escalating doses of RG3039 in up to 40 healthy volunteers. This will be the first clinical trial of a novel drug specifically designed to treat SMA and the first treatment approach which seeks to increase levels of the protein SMN.

"We are very pleased to have received approval to initiate human clinical trials with RG3039," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "RG3039 targets the core deficit of SMA and if this therapeutic approach is successful, it has the potential to arrest or slow disease progression and significantly improve patients' lives."

Patients lacking a functional SMN1 gene survive only because humans carry a second gene called SMN2 which produces low levels of SMN protein. RG3039, an orally bioavailable compound, is an inhibitor of an RNA processing enzyme which targets SMN2 and has been shown to increase production of SMN protein in cells derived from patients. In addition, RG3039 has been shown to improve mobility and lifespan in preclinical animal models of SMA. RG3039 is a new chemical entity, which is the subject of worldwide composition of matter patent applications which, if allowed, will remain in force until 2028 prior to any patent term extensions.

Source:

Repligen Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
Bacterial DNA promotes tau protein misfolding and aggregation, study shows